Synpromics announced as Best Emerging UK Synthetic Biotech Company at OBN Awards 2017
- Posted on 6 October, 2017
London, UK, 6th October 2017 / SynbiCITE congratulates Synpromics as the winner of Best Emerging UK Synthetic Biotech Company at OBN’s 9th Annual Awards Ceremony, held last night at Oxford Town Hall. The OBN Awards celebrate innovation and achievement across the UK life sciences industry, including emerging to late stage R&D companies as well as life science investors.
Synpromics, the leader in gene control, creates highly specific synthetic promoters designed to drive gene expression at the desired level and specificity in any cell type, tissue or environmental condition. The company has developed PromPT®, its multi- dimensional bioinformatics database that enables product-specific promoter design and selection empowering the next generation of cell and gene based medicines and bioprocessing applications.
In sponsoring this award, we are supporting the growth of the UK’s burgeoning synthetic biology industry, a core aim of SynbiCITE.
The 3 finalist companies under consideration for this award were:
• Synpromics Ltd
• Chain Biotech
• Oxford Genetics
Dr John Collins, Commercial Director of SynbiCITE, said “All the SynBio companies at the OBN awards represent the very best of synthetic biology in the UK, and were selected from a broad landscape of more than 110 companies across the country. We are privileged to be able help them work towards commercialisation of ground breaking and disruptive technology, turning up-starts to start-ups, and start-ups to grown-ups.”
You can find out more about the event at http://www.obn-awards.com
For more information, contact:
Dr John Collins, Commercial Director
T: +44 (0) 7876 750 624
Media Relations, Sciad Communications:
Richard Anderson, Managing Partner
T: +44 (0)7973 950376
Notes to Editors
SynbiCITE is a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting the adoption and use of synthetic biology by industry. SynbiCITE is a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting the adoption and use of synthetic biology by industry. SynbiCITE and our partners across the UK and globally are committed to developing this technology through responsible innovation which encompasses ethical, societal and environmental considerations.
Share this article:
People also read
Evonetix raises $30 million USD (£23 million GBP)
Series B investment led by west-coast investor Foresite Capital, with all existing investors participating in the roundFunds will be used to accelerat...
Evonetix collaborates with imec to scale-up chip-based technology production for third generation DNA synthesis platform
CAMBRIDGE, UK, and LEUVEN, Belgium, 13 January 2020 – EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scala...
Biotech firm MiAlgae secures £1m to turn whisky by-products into pet and fish food
An Edinburgh-based biotech startup which turns whisky distillation by-products into pet and fish food has received investment of £1 million.MiAlgae pr...